GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward

NCT06977438 on ClinicalTrials.gov · last registry update 2026-10-02

An unusually large phase 4: 1,020 participants, more than double the 75 typical for the stage. Due to report 31 January 2031. Primary outcome, as filed: Body Mass Index (BMI) Reduction. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of Minnesota
Sponsor type: Other
Enrollment: 1,020
Started: 2026-10-15
Primary completion: 2031-01-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Body Mass Index (BMI) Reduction

Conditions studied

Obesity, Childhood

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.